Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04867369 · ClinicalTrials.gov registry record · Phase 4
Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
NCT04867369: Completed Phase 4 study, sponsored by NYU Langone Health.
NCT04867369 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 160 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04867369, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
Study Summary
A phase IV, randomized, single-blind, single-center study measuring the effects of Pecs II block with 0.25% bupivacaine versus surgeon infiltration with 0.25% bupivacaine on postoperative pain control and opioid utilization in participants who undergo open subpectoral tenodesis.
Primary Outcome
Opioid utilization is calculated as morphine milligram equivalents (MME); measurement includes opioid utilization during surgery.
Interventions
- DRUG Bupivacaine 20mL 0.5%
- DRUG Bupivacaine 20mL 0.25%
- DRUG Bupivacaine up to 15mL 0.25%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2021-07-14 |
| Est. Completion | 2023-11-11 |
| Phase | Phase 4 |
What the finished NCT04867369 record still lists
NCT04867369 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 3 interventions - of which Bupivacaine 20mL 0.5% is the first listed.
NCT04867369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04867369 about?
NCT04867369 is a clinical study titled "Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis". A phase IV, randomized, single-blind, single-center study measuring the effects of Pecs II block with 0.25% bupivacaine versus surgeon infiltration with 0.25% bupivacaine on postoperative pain control and opioid utilization in participants who undergo open subpectoral tenodesis.
What is the current status of trial NCT04867369?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2021-07-14. Estimated completion is 2023-11-11.
What interventions are being tested in trial NCT04867369?
The interventions under investigation include: Bupivacaine 20mL 0.5% (DRUG), Bupivacaine 20mL 0.25% (DRUG), Bupivacaine up to 15mL 0.25% (DRUG).
Who is sponsoring clinical trial NCT04867369?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04867369's enrollment target sits among peer trials
160 507th of 2000 higher than 1,485 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI